BioInvent International AB (BINV) - Total Liabilities
Based on the latest financial reports, BioInvent International AB (BINV) has total liabilities worth Skr105.93 Million SEK as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
BioInvent International AB - Total Liabilities Trend (2000–2024)
This chart illustrates how BioInvent International AB's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
BioInvent International AB Competitors by Total Liabilities
The table below lists competitors of BioInvent International AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Fountaine Pajo
PA:ALFPC
|
France | €185.90 Million |
|
Gaon Group Ltd
TA:GAGR
|
Israel | ILA604.16 Million |
|
ECB Bancorp Inc.
NASDAQ:ECBK
|
USA | $1.43 Billion |
|
Sinch AB (publ)
LSE:0RBI
|
UK | Skr1.87 Billion |
|
Silver Mountain Resources Inc
V:AGMR
|
Canada | CA$31.60 Million |
|
Chongkundang
KO:001630
|
Korea | ₩713.67 Billion |
|
Sino-Ocean Group Holding Limited
F:3SD
|
Germany | €157.01 Billion |
|
Isu Chemical Co Ltd
KO:005950
|
Korea | ₩665.04 Billion |
Liability Composition Analysis (2000–2024)
This chart breaks down BioInvent International AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.59 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BioInvent International AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BioInvent International AB (2000–2024)
The table below shows the annual total liabilities of BioInvent International AB from 2000 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr103.42 Million | +14.34% |
| 2023-12-31 | Skr90.45 Million | -14.74% |
| 2022-12-31 | Skr106.09 Million | +32.08% |
| 2021-12-31 | Skr80.32 Million | +35.82% |
| 2020-12-31 | Skr59.14 Million | +4.35% |
| 2019-12-31 | Skr56.67 Million | +72.90% |
| 2018-12-31 | Skr32.78 Million | -17.69% |
| 2017-12-31 | Skr39.82 Million | -13.17% |
| 2016-12-31 | Skr45.86 Million | +83.50% |
| 2015-12-31 | Skr24.99 Million | +15.28% |
| 2014-12-31 | Skr21.68 Million | -33.15% |
| 2013-12-31 | Skr32.43 Million | -52.94% |
| 2012-12-31 | Skr68.92 Million | +1.64% |
| 2011-12-31 | Skr67.81 Million | +6.21% |
| 2010-12-31 | Skr63.84 Million | -9.59% |
| 2009-12-31 | Skr70.61 Million | +10.11% |
| 2008-12-31 | Skr64.13 Million | +12.74% |
| 2007-12-31 | Skr56.88 Million | +48.99% |
| 2006-12-31 | Skr38.18 Million | -19.36% |
| 2005-12-31 | Skr47.34 Million | +84.02% |
| 2004-12-31 | Skr25.73 Million | -32.70% |
| 2003-12-31 | Skr38.23 Million | -26.71% |
| 2002-12-31 | Skr52.16 Million | +135.63% |
| 2001-12-31 | Skr22.14 Million | -36.07% |
| 2000-12-31 | Skr34.62 Million | -- |
About BioInvent International AB
BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company's drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and a type of blood cancer; BI-1206, an a… Read more